The research, led by an international team headquartered at the Institute of Functional Genomics of Montpellier in France, focused on the Hippo pathway, an ancient signaling cascade best known for controlling organ size and tissue growth. At the heart of this pathway sits YAP1, a transcriptional co-activator that, together with its DNA-binding partner TEAD1, switches genes on and off in response to mechanical and developmental cues. When the researchers examined neural stem-cell cultures derived from adult spinal cord ependymal cells, they noticed something unexpected: as the cells multiplied in neurospheres, the levels of YAP1 and TEAD1 fell precisely at the moment when the first oligodendrocyte progenitor cells, identified by the marker PDGFRA, began to emerge.

To understand what was happening at the molecular level, the team exploited an elegant genetic tool: mice in which a fluorescent protein is knocked into the Pdgfra gene, allowing nascent oligodendrocyte progenitors to glow green under the microscope. Using fluorescence-activated cell sorting, the researchers isolated these newly specified progenitors from the surrounding neurosphere cells and subjected them to parallel transcriptomic and proteomic profiling, capturing both the RNA messages and the protein output of each population. The data revealed that OPC formation was accompanied by a coordinated upregulation of chromatin remodeling factors, the molecular machines that restructure DNA to make new gene programs accessible, while stem-cell-associated markers such as EGFR, HES1, and tenascin-C were progressively silenced.

Perhaps the most intriguing discovery concerned the transcription factor code carried by the proliferating neurosphere cells. Rather than being committed to a single identity, these cells displayed a remarkable hybrid profile, simultaneously expressing astrocytic regulators such as NFIA and SOX9 alongside oligodendrocytic factors including OLIG1/2, SOX4, NKX2.2, and TCF4. When differentiation was triggered, the oligodendrocytic factors were selectively retained in the cells that went on to become PDGFRA-positive progenitors, while they faded away in the remaining population that adopted other fates. This bivalent state suggests that adult spinal cord stem cells exist in a poised configuration, with both lineage programs primed and the outcome determined by external signals, of which YAP1 now appears to be a decisive one.

The functional experiments delivered the most dramatic results. When the researchers deleted the Yap1 gene in neurosphere cultures, the loss of this single protein was enough to tilt the entire system: the cells preferentially embarked on oligodendrocytic differentiation while astrocytic gene expression was suppressed. At the same time, genes associated with ependymal identity and motile cilia, the hair-like projections that characterize the cells lining the spinal cord canal, were downregulated. In other words, removing YAP1 did not merely nudge the cells along one path; it actively dismantled their ependymal heritage while unlocking the myelinating potential that regenerative medicine most wants to exploit.

The mirror-image experiment proved equally revealing. When the team introduced a constitutively active form of YAP1, a mutant protein that cannot be switched off, the consequences were severe. The cells entered an abortive attempt at cell-cycle activation that ended in widespread cell death, differentiation along both glial lineages was blocked entirely, and the surviving cells were driven toward an ependymal-like transcriptional program. This forced identity included upregulation of CD24a, a well-known ependymal surface marker, and cilia-associated proteins such as rootletin, encoded by the CROCC gene, which anchors the ciliary base. The message was unambiguous: too much YAP1 locks the cells in an immature, ependymal-like state, while removing it liberates their capacity to become oligodendrocytes.

These findings carry particular weight in the context of spinal cord injury, a devastating condition affecting hundreds of thousands of people worldwide with no effective regenerative treatment. After injury, the endogenous stem cells of the spinal cord respond robustly, but their response is counterproductive: the astrocytes they generate contribute to the glial scar, a dense barrier that physically and chemically inhibits axonal regrowth. Oligodendrocytes, by contrast, could remyelinate the stripped nerve fibers that survive the initial trauma, potentially restoring conduction and function. The new data suggest that pharmacologically dampening YAP1 activity in the injured spinal cord might redirect the endogenous stem-cell response away from scarring and toward repair, a concept that could reshape therapeutic strategies for paralysis.

The study also carries a broader message about the biology of the Hippo pathway in the nervous system. YAP1 has been implicated in neural stem-cell maintenance in the developing brain and in various cancers, where aberrant activation drives proliferation. Its role in adult spinal cord stem cells appears more nuanced, acting not simply as a growth promoter but as a guardian of ependymal identity that must be released for glial specification to proceed. The fact that forced activation proved cytotoxic adds an important note of caution for any therapeutic approach, since indiscriminate YAP1 manipulation could harm rather than heal, highlighting the need for precisely calibrated interventions that reduce, rather than amplify, its activity.

Technically, the work stands out for its multi-omic rigor. By combining transcriptomics and proteomics on the same purified cell populations, validating findings across genetic knock-in mice, knockout cultures, and constitutive activation experiments, and cross-referencing gene sets against single-cell atlases of both mouse and human spinal cord, the researchers built a layered evidence base in which each observation reinforces the others. The identification of a shared ependymal signature, including ninety-one genes downregulated upon YAP1 loss that overlap with previously defined ependymal markers, provides a quantitative framework other labs can now apply to their own models of glial specification and spinal cord regeneration.

What remains to be shown is whether the same switch operates in the living injured spinal cord and whether it can be safely toggled in vivo. Translating the cell-culture findings into animal models of contusion injury, and ultimately into human tissue, will require demonstrating that YAP1 modulation improves myelination and functional recovery without triggering tumor-like overgrowth or excessive cell death. Even so, the identification of a single, druggable pathway node controlling the oligodendrocyte-astrocyte fate decision marks a genuine conceptual advance. The quiet stem cells of the adult spinal cord have been waiting with their regenerative potential locked away, and science has just found one of the keys.

Subject of Research: Hippo/YAP1 signaling control of oligodendrocyte versus astrocyte fate decisions in adult spinal cord ependymal stem cells

Article Title: Hippo/YAP1 signaling regulates the Oligodendrocyte–Astrocyte fate switch and ependymal gene expression in adult spinal cord stem cells

Article References: Hippo/YAP1 signaling regulates the Oligodendrocyte–Astrocyte fate switch and ependymal gene expression in adult spinal cord stem cells. (n.d.). https://doi.org/10.1007/s00018-026-06294-y

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06294-y

Keywords: Hippo pathway, YAP1, spinal cord injury, neural stem cells, ependymal cells, oligodendrocytes, astrocytes, oligodendrocyte progenitor cells, PDGFRA, gliogenesis, myelination, regenerative medicine